Industry S Science News
Was this odd animal the world’s first milk suckler?
Ancient swimming creature provides clues to when nursing evolved
Industry headlines from across biotech and life sciences, gathered from the industry press and linked straight to the publisher. Every story links straight to its publisher.
Industry S Science News
Ancient swimming creature provides clues to when nursing evolved
Industry P Pharmafile
Amplio Pharma has reported phase 1b results for NovoBioJect, an investigational combination of low-dose methotrexate (MTX) and novobiocin being developed as a potential first-line treatment for rheumatoid arthritis (RA). In a 12-patient study, a single dose of NovoBioJect produce…
Industry P pharmaphorum
Adecto, Aviceda wind down, as Caribou seeks options Phil.Taylor Wed, 07/10/2026 - 10:38
Industry
Pharmaceutical Technology
KymaThera plans to dose the first patients in its Phase I trial on oral, selective PI3Kα inhibitor, K-1728, in breast cancer in Q4 2026.
Industry P Pharmaceutical Executive
CORXEL’s chief medical value discusses how GLP-1s are becoming a chronic disease platform.
Industry P Pharmaceutical Executive
What North American and APAC sponsors need to know about EU Joint Clinical Assessment — and why EMA approval doesn't guarantee reimbursement.
Industry P pharmaphorum
ViiV's Cabenuva enhances control of unsuppressed HIV Phil.Taylor Wed, 07/10/2026 - 09:16
Industry B BioTechniques
Original story from Cell Press. Forget bricks and mortar, scientists hoping to build houses on other worlds are turning to two unexpected building materials: gelatin and yeast. Mars is a terrible place to build a house. It’s bitterly cold, blasted by radiation and a near vacuum.…
Industry
STAT Biotech
Exon-skipping drugs present a critical test for the FDA’s goal of encouraging treatments for rare disease.
Industry
STAT Biotech
Caribou Biosciences is shutting down after failing to raise the money necessary to fund a late-stage clinical trial of its off-the-shelf CAR-T therapy for lymphoma.
Industry
Clinical Trials Arena
Trial governance strategies were a key theme at this year’s OCT SoCal conference, with consideration also given to the state of US trial regulation. The post OCT SoCal 2026: Sound governance and collaboration lead the way as regulation percolates appeared first on Clinical Trials…
Industry
Labiotech
September is often a strong month for the biopharma sector as the industry returns from the summer lull, keen on forging biotech deals. The post Top biotech deals in September 2026 appeared first on Labiotech.eu. © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplicatio…
Industry
European Biotechnology
Exclusive European data from BIO-Europe’s inaugural C-suite survey, shared with European Biotechnology, shows a sector expecting better funding conditions while struggling with investor caution. Among 69 executives at European-headquartered companies, 84% identify investor risk a…
Industry
Pharmaceutical Technology
Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives.
Industry
Inside Precision Medicine
Mitochondrial DNA can offer clues as to the severity of cancer and is associated with variations in the expression of genes affecting response to chemotherapy. The post Mitochondria Closely Linked with Cancer Progression appeared first on Inside Precision Medicine.
Industry S Science News
The landmark release of 722 papers targeting 372 unsolved problems draws amazement—and criticism
Industry S Science News
Biotech executive Steven Quay may be in contention for leadership role in infectious disease institute
Industry S Science News
Find in Spanish cave provides rare window into the domestic lives of our closest relatives
Industry
BioCentury
BIOCENTURY | MANAGEMENT TRACKSINSMED SEEKING CFO, PLUS C-SUITE ADDITIONS FOR IOVANCE, VIRTriGemX Bio rebrands, retools leadership team
Industry
BioCentury
BIOCENTURY | DISCOVERY & TRANSLATIONCNS OLIGO DELIVERY – THE NEXT FRONTIER FOR BRAIN SHUTTLESPreclinical studies are revealing the design rules for systemic delivery to the brain as the first shuttle-oligo conjugate enters the clinic
Industry
Nature Reviews Drug Discovery
Industry N Nature Biomedical Engineering
Industry
Nature Reviews Drug Discovery
Industry
Inside Precision Medicine
People taking statins were 15% less likely to develop open-angle glaucoma at five years, while those with the disease had substantially lower rates of surgery and laser treatment. The post Statin Use Linked to Lower Glaucoma Risk and Less Need for Intensive Treatment appeared fir…
Industry
GEN
This GEN webinar follows oligo quantification from method development through conjugate characterization. The post Lock Down the Critical Factors in Oligo and Oligo-Conjugate Characterization with Stunner and Honeybun appeared first on GEN - Genetic Engineering and Biotechnology…
Industry
GEN
This GEN Spotlight on Biologics Standards for Innovation, Quality and Access brings together experts from across biopharma, standards development, and analytical science to examine the challenges of testing increasingly complex modalities, including monoclonal antibodies, cell an…
Industry
BioCentury
BIOCENTURY | EMERGING COMPANY PROFILEROUGETX: REATTACHING PERICYTES TO STABILIZE VESSELS IN HHTLeiden University Medical Center spinout raises $58M series A to take an oral small molecule into the clinic for hereditary hemorrhagic telangiectasia
Industry B BioPharm International
New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
Industry
MedCity News
Forbion’s new capital will support two funds that will invest in about 30 companies combined. The new funds for Netherlands-based Forbion come amid a decline in VC fundraising and investments in Europe, according to Pitchbook. The post Forbion Bucks VC Fundraising Trends, Reeling…
Industry P pharmaphorum
Why Klick Health, Oxford PharmaGenesis chose to join forces Jonah.Comstock Tue, 06/10/2026 - 18:03
Industry P Pharmaceutical Executive
Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.
Industry P Pharmaceutical Executive
Social listening can help medical affairs and medical information teams identify knowledge gaps, strengthen scientific exchange and respond to changing stakeholder needs faster and at greater scale.
Industry
BioPharma Dive
More than half of the company’s value was wiped out by findings that appear to erase a chance to battle Johnson & Johnson and others for market share.
Industry P pharmaphorum
Taking the microbiome seriously, with Sam Possemiers Nicole.Raleigh Tue, 06/10/2026 - 15:41
Industry
MedTech Dive
Lobo will step down on Dec. 31 as CEO after more than 15 years at Stryker. Chief operating officer Spencer Stiles will lead the company.
Industry
GEN
Short-read RNA sequencing reporting the modifications that alter protein output is starting to make epitranscriptomics indispensable for patient selection in precision medicines. The post The Epitranscriptome Heads Toward Clinical Necessity appeared first on GEN - Genetic Enginee…
Industry
GEN
With no cure available for prion diseases, researchers are striving to improve assay sensitivity and exploit the benefits of real-time monitoring to support the development of better diagnostic and treatment approaches. The post Investigating Prions and Protein Aggregation at Hig…
Industry
Inside Precision Medicine
A new strategy from Boston Children’s targets the molecular machinery that keeps pain-sensing neurons switched on after injury, offering a potential new approach to chronic neuropathic pain. The post Experimental Peptide Quiets Chronic Pain Signals While Preserving Protective Pai…
Industry P pharmaphorum
Europe's Largest Gathering for ADC Innovation Sara.Scarpinati Tue, 06/10/2026 - 14:57
Industry
STAT Biotech
AstraZeneca opened a new R&D site in Kendall Square yesterday, celebrating a $1 billion investment in the unsettled center of U.S. biotechnology after a spate of Chinese dealmaking.